To that end, the administration of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood sugar by increasing glucose in the urine, in a DSS rat model resulted in improved outcomes pertaining to myocardial hypertrophy, fibrosis, and left ventricular diastolic dysfunction. This evidence concerns the gene SLC5A2 and cardiac hypertrophy.